Related Experiment Videos
Development of gene-specific double-stranded RNA drugs
1Department of Biochemistry and Molecular Biology, University of Southern Alabama, College of Medicine, Mobile 36688-0002, USA. sbarik@jaguar1.usouthal.edu
Annals of Medicine
|October 30, 2004
Summary
Double-stranded RNA (dsRNA) and RNA interference (RNAi) offer targeted gene silencing for novel therapies. This technology shows promise for treating diverse diseases, including cancer and viral infections.
Area of Science:
- Molecular Biology
- Genetics
- Biotechnology
Background:
- Double-stranded RNA (dsRNA) possesses unique properties like stability and protein affinity.
- RNA interference (RNAi) utilizes short interfering RNA (siRNA) for potent and selective post-transcriptional gene silencing (PTGS).
Purpose of the Study:
- To review the biological synthesis, metabolism, and effects of dsRNA, focusing on siRNA and RNAi.
- To explore the clinical, pharmacological, and pharmaceutical potential of dsRNA as a therapeutic agent.
Main Methods:
- Review of existing literature on dsRNA biology and RNAi mechanisms.
- Analysis of preclinical and clinical data regarding dsRNA-based therapeutics.
Main Results:
- Understanding dsRNA design and delivery has enabled gene therapy without gene knockout.
- dsRNA technology has demonstrated potential in various therapeutic applications.
Conclusions:
- dsRNA holds significant promise for treating a wide range of metabolic and infectious diseases.
- Therapeutic applications include cancer, macular degeneration, neural disorders, autoimmune diseases, and viral infections like AIDS and hepatitis.